Skip to main content

Table 1 Pre-treatment patient demographics

From: Effect of oxaliplatin plus 5-fluorouracil or capecitabine on circulating and imaging biomarkers in patients with metastatic colorectal cancer: a prospective biomarker study

Patient demographic Value
Total patients 20
Sex: number (percentage)
 Male 17 (85%)
 Female 3 (15%)
Age: (years)
 Mean 69
 Range 58–80
WHO performance status: number (percentage)
 0 7 (35%)
 1 12 (60%)
 2 1 (5%)
Pre-treatment CEA (μg/L):
 Mean 384
 Range 3–2897
Pre-treatment LDH (IU/L):
 Mean 2279
 Range 45–11,346
Chemotherapy regimen: number (percentage)
 Oxaliplatin and 5FU 18 (90%)
 Oxaliplatin and capecitabine 2 (10%)